Results 181 to 190 of about 15,701 (194)

Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes

Diabetes Care, 2015
Sanjay R Patel, Dacheng Liu, Hans J Woerle   +2 more
exaly  

Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

Diabetes Care, 2015
Ralph A Defronzo, Sanjay R Patel, Dacheng Liu   +2 more
exaly  

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Diabetes Care, 2016
Julio Rosenstock, Hans J Woerle, Uli C Broedl   +2 more
exaly  

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

Diabetes Care, 2015
Ilkka Tikkanen, Afshin Salsali, Uli C Broedl   +2 more
exaly  

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Diabetes Care, 2013
Hans-Ulrich Haring, Hans J Woerle, Uli C Broedl   +2 more
exaly  

Empagliflozin Directly Improves Diastolic Function in Human Heart Failure

European Journal of Heart Failure, 2018
Steffen Pabel, Petros Tirilomis, Julian Mustroph   +2 more
exaly  

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Diabetes Care, 2014
Hans-Ulrich Haring, Uli C Broedl, Hans J Woerle   +2 more
exaly  

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Diabetes Care, 2018
Silvio E Inzucchi, Bernard Zinman, David Fitchett   +2 more
exaly  

Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

Diabetes, Obesity and Metabolism, 2014
Christopher S Kovacs, H J Woerle, U C Broedl   +2 more
exaly  

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

Clinical Pharmacology in Drug Development, 2013
Leo Seman, Sreeraj Macha, Gerhard Nehmiz   +2 more
exaly